SK Biopharm Accelerates AI-Driven Epilepsy Management Innovation with Launch of JV 'Menthis Care'

On October 21, SK Biopharm announced that it has established a joint venture (JV) named Menthis Care with Eurofarma, a leading pharmaceutical company in Latin America, to commercialize an AI-based epilepsy management platform.

Menthis Care. SK Biopharm

원본보기 아이콘

Since 2018, SK Biopharm has been developing its proprietary AI technology for brainwave analysis and wearable device capabilities, accumulating expertise in seizure prediction and real-time monitoring for patients. The establishment of this JV is expected to mark the official entry of SK Biopharm into the AI digital healthcare market, leveraging these technological strengths.

Menthis Care plans to develop a patient-customized alert system centered on real-time seizure prediction technology and a data-driven clinical decision support platform, both based on SK Biopharm’s core technologies. Through this platform, the company aims to support patients’ treatment processes with data and create an environment that enables personalized management.

As part of its North American market expansion strategy, Menthis Care has also established a base at the MaRS Discovery District in Toronto, Canada. This location is the largest innovation hub in North America, where research institutes, startups, and investor networks in the healthcare and life sciences fields converge. The company aims to further advance its seizure detection and prediction algorithms to a level suitable for clinical validation by expanding its organization with local talent and strengthening its academic and industry networks.

Eurofarma, a leading pharmaceutical company in Latin America, will take the lead in business strategy development and securing AI training data for the JV, drawing on its years of investment experience in the digital healthcare sector. Since 2022, SK Biopharm and Eurofarma have collaborated on the launch of the innovative epilepsy drug cenobamate in Latin America, and with the establishment of this JV, they have expanded their partnership into the digital healthcare domain.

Hassan Kotob, who has been appointed as the inaugural CEO of Menthis Care, is the former CEO of Brain Scientific, an AI-based neuro-monitoring company, and is an expert with more than 30 years of experience in the healthcare and technology industries.

Hassan Kotob, CEO of Menthis Care, stated, "Menthis Care aims to help epilepsy patients lead safer and more independent lives through AI technology. By combining the innovative capabilities of SK Biopharm and Eurofarma, we will establish a new standard in epilepsy management based on AI prediction technology."

Lee Donghun, CEO of SK Biopharm, said, "SK Biopharm is opening new possibilities for patient treatment not only through innovative new drugs but also through AI-based digital healthcare. Through Menthis Care, we will drive patient-centered treatment innovation by integrating AI technology."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.